PTB Reports, 2020, 6, 2, 50-54.
DOI: 10.5530/PTB.2020.6.9
Published: March 2020
Type: Research Article
Authors: Faisal Al-Otaibi, Mohamed Soliman Imam, Randa Mansour Abdel-Sattar Ahmed, Amsha Alotaibi, Asma Alotaibi, Amal Alotaibi, Wesam Alsuwaid, and Yousef Ahmed Alomi
Author(s) affiliations:
Faisal Al-Otaibi, Ph. D, Assistant Professor, College of Pharmacy, Pharmacy Patrice Department, Shaqra University, Saudi Arabia.
Mohamed Soliman Imam, Ph. D, Assistant Professor, Dean, College of Pharmacy, Shaqra University, Saudi Arabia.
Randa Mansour Abdel-Sattar Ahmed, Ph.D, Biomedical Science Department, College of Pharmacy, Shaqra University, Saudi Arabia.
Amsha Alotaibi, Pharm D, Clinical Pharmacist, College of Pharmacy, Pharmacy Patrice Department, Shaqra University, Riyadh, Saudi Arabia.
Asma Alotaibi, Pharm D, Clinical Pharmacist, College of Pharmacy, Pharmacy Practice Department, Shaqra University, Saudi Arabia.
Amal Alotaibi, Pharm D, Clinical Pharmacist, College of Pharmacy, Shaqra University, Saudi Arabia.
Wesam Alsuwaid, Pharm D, Clinical Pharmacist, College of Pharmacy, Pharmacy Practice Department, Shaqra University, Saudi Arabia.
Yousef Ahmed Alomi*, BSc. Pharm, MSc. Clin Pharm, BCPS, BCNSP, DiBA, CDE, Critical Care Clinical Pharmacists, TPN Clinical Pharmacist, Freelancer Business Planner, Content Editor and Data Analyst, Riyadh, Saudi Arabia.
Abstract
Objectives: To survey the pharmacist privilege in Saudi Arabia with an emphasis on pharmacist prescribing and therapeutic interchange. Methods: This is a 4-month cross-sectional survey of pharmacists privilege in Saudi Arabia. The study consists of two parts: the first part collects demographic information and the second part comprises 28 questions divided into four domains. These domains were derived from the previous literature and from the standards and regulations described by the American Society of Health-System Pharmacists (ASHP). The domains were privilege management and resources, pharmacist prescribing and therapeutic interchange, clinical and administration privilege, drug monitoring and healthcare education. We used 5-point Likert response scale system with closeand open-ended questions to obtain responses. The questionnaire was distributed in an electronic format to the director of pharmacy of various hospitals, deputy director, pharmacy quality management, clinical pharmacy coordinators, or any pharmacist assigned on behalf of hospital’s director of pharmacy. The study discussed and analyzed pharmacist privilege in Saudi Arabia with an emphasis on pharmacist prescribing and therapeutic interchange. All data were obtained through the Survey Monkey system. Results: The survey was distributed to 36 hospitals. The pharmacist privilege of prescribing was available only at 12 (32.14%) hospitals. over-the-counter (OTC) medications (19 (90.48%)) and vitamins (14 (66.67%)) were most of the medications with pharmacist privilege of prescribing followed by minerals (11 (52.38%)) and electrolytes (10 (47.62%)), whereas NSAIDs (23 (63.89%)), Vitamins (19 (52.78%)), electrolytes (17 (47.22%)) and antihistamine (15 (41.67%)) were through therapeutic interchange program. Most of the pharmacists prescribing medication was through ambulatory care clinic (19 (52.78%)) and when prescription was cosigned by the physician (19 (52.78%)). The average score of pharmacist privilege in the hospital’s computerized physician order entry (CPOE) was 3.17 (63.46%), whereas the average score of pharmacist privilege in the hospital’s CPOE alerting system was 2.97 (59.46%). Conclusion: In the Kingdom of Saudi Arabia, pharmacist privilege in prescribing medications is very low. Most of the medications prescribed by the pharmacist were OTC drugs. Thepharmacist privilege in the Computerized Physician Order Entry is not adequate. We highly recommend the implementation of a comprehensive pharmacist privilege system and regulations ed in Saudi Arabia.